Frontlight ResearchEarly access
Taking people in BelgiumPhase 1
How the body processes inhaled colistimethate in healthy adults and bronchiectasis patients
Tests how colistimethate sodium moves through the body in healthy adults and adults with bronchiectasis.
Key facts
- Who runs it
- Zambon S.p.A.
- Where
- Edegem and Mechelen, BelgiumSee the 2 sitesAlso in 2 other countries, 3 sites
- Trial code
- Registry title
- A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non‑cystic fibrosis bronchiectasis (NCFB) (Part 2)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 55 people, planned
- Started
- 2 Nov 2026
- Expected to end
- 31 May 2027
- Type of study
- Interventional
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adults (Part 1) and adults with non-cystic fibrosis bronchiectasis (Part 2). It studies how the body handles colistimethate sodium (CMS) over time.
- Age
- 18 years or older
- Sex
- All sexes can join
Where in Belgium
Also in 2 other countries, 3 sites
- SGS BelgiumEdegem, BelgiumTaking people
- EmmauesMechelen, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- How the body processes inhaled colistimethate in healthy adults and bronchiectasis patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 28 October 2026